Free Trial Information
BioCentury | Jan 29, 2021
Management Tracks

Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO

...joining Orchard a year ago, Parker held commercial leadership roles at Celgene Corp., Shire plc’s NPS...
Read More
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...Northwestern University describes a new therapeutic to deplete GPX4. The researchers designed functional lipoprotein-like nanoparticles (Flip-NPs...
...deplete cholesterol in the cell membrane, leading to a reduction in GPX4 expression and ferroptosis. Flip-NPs...
Read More
BioCentury | Jul 18, 2019
Distillery Therapeutics

Small molecule NPR1 inhibitors for itch

DISEASE CATEGORY: Dermatology INDICATION: Itch NIH researchers identified 15 small molecule human NPR1 inhibitors through cell-based screening that could treat itch. The compounds inhibited NRP1, a receptor for a neuropeptide that promotes itch, with IC...
Read More
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

...indication. Takeda's Shire plc unit gained the analog of GLP-2 through its 2015 acquisition of NPS...
Read More
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...also venture partner at Blackstone, will join the company's board along with former CEO of NPS...
Read More
BioCentury | Feb 20, 2019
Distillery Therapeutics

Neurology

INDICATION: Pain Rat studies suggest nanoparticles loaded with Leu-enkephalin-lipid conjugate could help treat pain. In a rat model of chemical-induced pain, nanoparticles loaded with a conjugates consisting of the neuropeptide Leu-enkephalin linked to the lipid...
Read More
BioCentury | May 23, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of NPY1R bound to tool compound antagonists or its endogenous agonist NPY could guide the design of compounds that antagonize or agonize the receptor for obesity, cancer or bone loss....
Read More
BioCentury | Oct 20, 2017
Clinical News

EC approves Amgen's Mimpara for pediatric indication

...has rights outside of China, Japan, North and South Korea and Taiwan to cinacalcet from NPS...
...plc (LSE:SHP; NASDAQ:SHPG) acquired. Kyowa has rights in the Asian countries from a deal with NPS...
Read More
BioCentury | Jul 18, 2017
Distillery Techniques

Drug delivery; drug platforms

...nanoparticles (AC-NPs) could enhance immune responses to radiotherapy plus checkpoint inhibitors to treat cancer. The AC-NPs...
...tumor cells after radiotherapy-induced cell death. In xenograft mouse models of melanoma and breast cancer, AC-NPs...
...survival compared with free tumor antigens plus radiotherapy and the antibody. In the melanoma model, AC-NPs...
Read More
BioCentury | Jul 13, 2017
Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
Read More
Items per page:
1 - 10 of 854